Generics Bulletin“The more time I spend here, the more confused I become.” That was the verdict of Sandoz CEO Richard Saynor on the various frustrations of the US off-patent market, as he explored dysfunctional elemen
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Daiichi Sankyo Tries Wayfinder’s
ScripUS President Donald Trump’s ever-evolving stance on tariffs may be rattling the world and also has pharma on tenterhooks, but going down that path for generic medicines may be a doubled-edged sword or
Generics BulletinPreviously facing the prospect of a jury trial beginning next month, Jazz Pharmaceuticals has agreed in principle to pay $145m to resolve certain allegations that its US patent-litigation settlement a